atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
Reed Jobs is keen for his $1bn venture capital fund Yosemite to make a difference.
The 34-year-old runs an oncology-focused venture capital fund that manages more than $1bn in assets, and is in the UK looking for investment opportunities.
Read…
SMA is a rare, inherited condition that causes progressive muscle weakness, affecting movement, breathing and swallowing. People living with spinal muscular atrophy (SMA) in England are set to gain routine access to two potentially life-changing treatments, following our publication of final…
Attendees
Sponsors and Exhibitors
Contact us